Literature DB >> 7243210

3. Phenylephrine hydrochloride.

S M Meyer, F T Fraunfelder.   

Abstract

Phenylephrine hydrochloride is a potent, effective, relatively safe drug with few ocular side effects. Side effects from topical instillation are uncommon but include severe systemic cardiovascular effects with elevated blood pressure and stroke. Ten percent phenylephrine should be used with caution in patients with known cardiac disease, hypertension, aneurysms, long-standing insulin-dependent diabetes, or advanced arteriosclerosis. A 2.5% concentration is generally indicated for ophthalmic examination as well as for use in infants and in the elderly. Phenylephrine should not be used in patients with narrow-angle glaucoma, and it is also contraindicated in patients taking monoamine oxidase inhibitors or tricyclic antidepressants.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7243210     DOI: 10.1016/s0161-6420(80)35108-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Characterizing Current Attitudes and Practices for Human Subject Safety in Studies Involving Pupil Dilation.

Authors:  Jacob Szpernal; Joseph Carroll; Ryan Spellecy; Jane A Bachman Groth
Journal:  J Empir Res Hum Res Ethics       Date:  2020-11-02       Impact factor: 1.742

2.  Dilate the pupil and see the fundus.

Authors:  C I Phillips
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-16

Review 3.  Non-prescription sympathomimetic agents and hypertension.

Authors:  S S Chua; S I Benrimoj
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

Review 4.  Systemic adverse effects of topical ophthalmic agents. Implications for older patients.

Authors:  J P Diamond
Journal:  Drugs Aging       Date:  1997-11       Impact factor: 3.923

5.  Pupillary Dilation in Research: More than Meets the Eye.

Authors:  Jacob Szpernal; Jane A Bachman Groth; Niamh Wynne; Vesper Williams; Ryan Spellecy; Catherine Thuruthumaly; Joseph Carroll
Journal:  Curr Eye Res       Date:  2022-05-02       Impact factor: 2.555

6.  Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes.

Authors:  D S Chien; R D Schoenwald
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

Review 7.  Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions.

Authors:  Seanna R Grob; Luis A Gonzalez-Gonzalez; Mary K Daly
Journal:  Clin Ophthalmol       Date:  2014-07-03

8.  Budget impact model of Mydrane®, a new intracameral injectable used for intra-operative mydriasis, from a UK hospital perspective.

Authors:  Keith Davey; Bernard Chang; Christine Purslow; Emilie Clay; Anne-Lise Vataire
Journal:  BMC Ophthalmol       Date:  2018-04-19       Impact factor: 2.209

9.  Effective pupil dilatation with a mixture of 0.75% tropicamide and 2.5% phenylephrine: A randomized controlled trial.

Authors:  Adisak Trinavarat; Auengporn Pituksung
Journal:  Indian J Ophthalmol       Date:  2009 Sep-Oct       Impact factor: 1.848

10.  Long Term and Intensive Use of Ophthalmic Topical Corticosteroids and the Risk of Positive Doping Test in Athletes: A Case Report.

Authors:  Tohid Seif Barghi; Farzad Kobarfard; Ahmad Hashemian; Jayran Zebardast
Journal:  Asian J Sports Med       Date:  2015-09-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.